These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 33445051)

  • 1. IFN-γ
    Yadav S; Prakash J; Singh OP; Gedda MR; Chauhan SB; Sundar S; Dubey VK
    Cell Immunol; 2021 Mar; 361():104272. PubMed ID: 33445051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
    Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
    Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
    Choudhury R; Das P; De T; Chakraborti T
    Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.
    Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E
    Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological characterization of rLdTCP1γ for its prophylactic potential against visceral leishmaniasis in hamster model.
    Anand A; Balodi DC; Ramalingam K; Yadav S; Goyal N
    Mol Immunol; 2022 Jan; 141():33-42. PubMed ID: 34798496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis.
    Nico D; Martins Almeida F; Maria Motta J; Soares Dos Santos Cardoso F; Freire-de-Lima CG; Freire-de-Lima L; de Luca PM; Maria Blanco Martinez A; Morrot A; Palatnik-de-Sousa CB
    Front Immunol; 2018; 9():967. PubMed ID: 29867949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
    Das P; Paik D; Naskar K; Chakraborti T
    Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
    Bhaumik SK; Naskar K; De T
    Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
    Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF
    Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
    Stäger S; Smith DF; Kaye PM
    J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Live Attenuated Leishmania donovani Centrin Knock Out Parasites Generate Non-inferior Protective Immune Response in Aged Mice against Visceral Leishmaniasis.
    Bhattacharya P; Dey R; Dagur PK; Joshi AB; Ismail N; Gannavaram S; Debrabant A; Akue AD; KuKuruga MA; Selvapandiyan A; McCoy JP; Nakhasi HL
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004963. PubMed ID: 27580076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell engineered cTXN as new vaccine prospect against L. donovani.
    Suman SS; Kumar A; Singh AK; Amit A; Topno RK; Pandey K; Das VNR; Das P; Ali V; Bimal S
    Cytokine; 2021 Sep; 145():155208. PubMed ID: 32736961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis.
    Baharia RK; Tandon R; Sharma T; Suthar MK; Das S; Siddiqi MI; Saxena JK; Sundar S; Dube A
    PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003557. PubMed ID: 25745863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
    Bhowmick S; Ravindran R; Ali N
    Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis.
    Jaiswal AK; Khare P; Joshi S; Kushawaha PK; Sundar S; Dube A
    PLoS One; 2014; 9(9):e108556. PubMed ID: 25268700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visceral leishmaniasis: A novel nuclear envelope protein 'nucleoporins-93 (NUP-93)' from Leishmania donovani prompts macrophage signaling for T-cell activation towards host protective immune response.
    Singh MK; Jamal F; Dubey AK; Shivam P; Kumari S; Pushpanjali ; Bordoloi C; Narayan S; Das VNR; Pandey K; Das P; Singh SK
    Cytokine; 2019 Jan; 113():200-215. PubMed ID: 30001865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against Leishmania donovani: a step towards exploring novel vaccine candidate.
    Tandon R; Chandra S; Baharia RK; Misra P; Das S; Rawat K; Siddiqi MI; Sundar S; Dube A
    Parasitology; 2018 Apr; 145(4):508-526. PubMed ID: 28691653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice.
    Dey R; Dagur PK; Selvapandiyan A; McCoy JP; Salotra P; Duncan R; Nakhasi HL
    J Immunol; 2013 Mar; 190(5):2138-49. PubMed ID: 23338240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
    Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
    Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically Engineered Ascorbic acid-deficient Live Mutants of Leishmania donovani induce long lasting Protective Immunity against Visceral Leishmaniasis.
    Anand S; Madhubala R
    Sci Rep; 2015 Jun; 5():10706. PubMed ID: 26035062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.